News

Green light for stem cell study
Enlarge image

Clinical TrialsUK

Green light for stem cell study

15.08.2012 - The British stem cell specialist ReNeuron has received the go-ahead for its phase I trial with disabled stroke patients.

After having reviewed the safety data from the first two dose cohorts, the Data Safety Monitoring Board (DSMB) has recommended to continue the PISCES trial with ReN001. ReNeuron’s ReN001 cell therapy for stroke consists of a neural stem cell line. Until now, no adverse side effects have been found in the review period. Six patients have been included in the trial, the first 18 months ago. “We are delighted that the DSMB have given a favourable recommendation to proceed to the higher and penultimate dose in the PISCES stroke trial,” said ReNeuron’s chief executive Michael Hunt. The study is testing the safety and tolerability of the treatment of ascending doses of the ReN001 cells in patients with moderate to severe functional neurological impairments from their strokes in what is the world’s first fully regulated clinical trial. In June this year, the firm revealed that the first five PISCES patients showed reductions in neurological impairment and spasticity. These improvements were sustained in the longer-term. If everything goes on as planned, ReNeuron could apply for a phase II study in 2013.

http://www.european-biotechnology-news.com/news/news/2012-03/green-light-for-stem-cell-study.html

R&DUKIreland

29.07.2016 GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)5.70 SEK21.54%
  • QIAGEN NV (D)23.48 EUR12.29%
  • MOBERG PHARMA (S)44.10 SEK10.25%

FLOP

  • MOLOGEN (D)1.81 EUR-11.71%
  • NICOX (F)9.62 EUR-8.29%
  • SAREUM HOLDINGS (UK)0.72 GBP-6.49%

TOP

  • PROTHENA PLC (IE)55.05 USD57.5%
  • DIAMYD MEDICAL -B- (S)5.70 SEK37.3%
  • VERNALIS (UK)44.50 GBP31.9%

FLOP

  • MOLOGEN (D)1.81 EUR-38.4%
  • SANTHERA (CH)56.20 CHF-26.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)33.00 SEK1962.5%
  • NICOX (F)9.62 EUR425.7%
  • SAREUM HOLDINGS (UK)0.72 GBP213.0%

FLOP

  • BB BIOTECH (D)44.83 EUR-84.6%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.80 SEK-78.2%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 29.07.2016